Studies related to Symptoms of Schizophrenia and D-Serine

High Dose D-serine In The Treatment Of Schizophrenia

Effect Decrease
Trial Design Cohort
Trial Length 2-4 Weeks
Number of Subjects 42
Gender Both Genders
Notes for this study:
D-Serine at doses between 30-120mg/kg was dose-dependently effective in reducing all symptoms of schizophrenia, with 30mg/kg being ineffective on some (but not all) parameters. Improvements in symptoms appeared to correlate with blood D-serine concentrations

A Randomized, Double-blind, Placebo-controlled Comparison Study Of Sarcosine (N-methylglycine) And D-serine Add-on Treatment For Schizophrenia

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
In 60 persons with schizophrenia given 2,000mg D-serine daily for 6 weeks, D-serine supplementation failed to outperform placebo on all measured parameters while the reference drug (sarcosine) was effective at the same dose.

D-serine Added To Antipsychotics For The Treatment Of Schizophrenia

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 28
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Notes for this study:
Supplementation of 30mg/kg D-serine to schizophrenic patients for 6 weeks was able to reduce all symptoms of schizophrenia, and serum concentrations of D-serine were able to predict the improvements seen in rating scales.

D-serine Efficacy As Add-on Pharmacotherapy To Risperidone And Olanzapine For Treatment-refractory Schizophrenia

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 39
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
30mg/kg of D-serine daily in addition to antipsychotic therapy (risperidone or olanzapine) was able to improve negative, positive, depressive, and cognitive scores over 6 weeks with the improvement on symptoms being 4.3-20.6% (95% CI of SAS rating scale), 19.8-57.7% (95% CI of AIMS), and 14 patients on D-serine noted over a 20% improvement on negative and positive symptoms while only 2 subjects on placebo did.

Sarcosine Or D-serine Add-on Treatment For Acute Exacerbation Of Schizophrenia: A Randomized, Double-blind, Placebo-controlled Study

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 65
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
6 weeks supplementation of 2,000mg D-serine (compared to both placebo and an equal dose of sarcosine) has failed to outperform placebo when both were added to risperidone therapy.

A Multicenter, Add-on Randomized Controlled Trial Of Low-dose D-serine For Negative And Cognitive Symptoms Of Schizophrenia

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 195
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Notes for this study:
In 195 persons with schizophrenia already on antipsychotic treatment, the addition of 2,000mg D-serine daily for 16 weeks failed to outperform placebo at controlling positive and negative symptoms of schizophrenia and failed to significantly affect cognition.